
Employees of Daihatsu Motor Co. head to plant in Ikeda, Osaka Prefecture, to resume operation on Monday.
12:26 JST, May 7, 2024
IKEDA, Osaka (Jiji Press) — Daihatsu Motor Co. on Tuesday resumed production at its plant in Ikeda, Osaka Prefecture, western Japan, after suspending operations from late December last year due to its safety test fraud scandal.
All of Daihatsu’s four finished vehicle assembly plants in Japan are back online for the first time in about four months. The subsidiary of Toyota Motor Corp. will speed up the delayed delivery of vehicles for which it has received orders, as well as the improvement of existing models and the development of new models.
In February, Daihatsu, headquartered in Ikeda, started resuming production in stages for models confirmed safe by the transport ministry.
At the plant in Ikeda, the company will manufacture the Copen minivehicle and a model of the same name for Toyota.
Even after the resumption of operations at all of its domestic plants, Daihatsu’s production is expected to be less than 80% of the level in fiscal 2022, before the scandal came to light, partly due to delays in the introduction of new models.
Top Articles in Business
-
Japan, U.S. Name 3 Inaugural Investment Projects; Reached Agreement After Considerable Difficulty
-
Japan’s Major Real Estate Firms Expanding Overseas Businesses to Secure Future Growth, Focusing on Europe, U.S., Asia
-
Nippon Life Insurance’s U.S. Arm Sues OpenAI Over Legal Assistance Provided by ChatGPT
-
Transport Companies See Opportunity in Narita Expansion; Airlines, Railways Prepare to Meet Expected Growth in Demand
-
Amid Strait of Hormuz Blockade, Shipping Companies Scramble to Get Japan-Linked Vessels out of Persian Gulf
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Videos Plagiarized, Reposted with False Subtitles Claiming ‘Ryukyu Belongs to China’; Anti-China False Information Also Posted in Japan
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

